Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.32 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.32 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.32 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.32 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.30 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.30 |
| ▸ | CTSB | P07858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5029919 | 0.92 | MAPK1 (0.38) | LMNAMAPK1GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL6427748 | 0.91 | MAPK1 (0.34) | LMNAMAPK1GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL6428486 | 0.90 | SCN9A (0.33) | LMNAMAPK1JAK2CAPN1CTSB | |
| SCHEMBL6427759 | 0.88 | LMNA (0.35) | LMNAMAPK1GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL5031136 | 0.88 | LMNA (0.35) | LMNAMAPK1GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL6428642 | 0.86 | DCAF1 (0.40) | MAPK1 | |
| SCHEMBL5029993 | 0.84 | MEN1 (0.36) | LMNAMAPK1GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL13927747 | 0.84 | MAPK1 (0.38) | LMNAMAPK1NTRK1CAPN1CTSB | |
| SCHEMBL6426817 | 0.83 | MAPK1 (0.34) | LMNAMAPK1CAPN1CTSB | |
| SCHEMBL4139328 | 0.83 | TRPA1 (0.32) | PDPK1JAK2NTRK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | CNKSR1, NR3C2, CSNK2B | LMNA 3498/4885MAPK1 6/4885GUCY1B2 3406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.